InvestorsHub Logo
Followers 8
Posts 628
Boards Moderated 0
Alias Born 05/26/2021

Re: None

Wednesday, 10/06/2021 8:34:45 AM

Wednesday, October 06, 2021 8:34:45 AM

Post# of 13742
https://www.stocktitan.net/news/QNTA/medolife-rx-initiates-comparative-study-of-its-flagship-cbd-based-mnck3kl4aeht.html

“We know that polarized CBD, along with polarized Ibuprofen and Escozine®, are effective in inhibiting the COX-2 enzyme, as shown by the previous studies we have completed,” said Medolife CEO Dr. Arthur Mikaelian. “While we hope to further prove the hypothesis in future studies, the purpose of this study is to show the variance between COX-2 inhibition in standard CBD products that are currently on the market, which are non-polarized, when compared to our muscle rub product, which includes polarized CBD. We are beyond confident that the variance will be vast and that yet again we will prove we have one of the most effective products in the pain relief category available today.”
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.